Items where authors include "Parrish, C."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Chandler, T. orcid.org/0009-0001-1899-7510, Parrish, C., Karakantza, M. et al. (4 more authors) (2023) A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction. EJHaem, 4 (3). pp. 625-630. ISSN 2688-6146

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Müller, L.M.E., Migneco, G., Scott, G.B. et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426

Ahmedzai, S.H., Snowden, J.A. orcid.org/0000-0001-6819-3476, Ashcroft, A.J. et al. (19 more authors) (2019) Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Cook, G., Ashcroft, A.J., Cairns, D.A. et al. (17 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol, 3 (7). e340-e351.

Parrish, C., Morris, C.T.C.M., Williams, C.D. et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.

Seymour, F., Taylor, C., Gilson, S. et al. (10 more authors) (2023) Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study. In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, CA, USA. American Society of Hematology , p. 6602.

Mueller, L.M.E., Parrish, C., Migneco, G. et al. (6 more authors) (2017) Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy. In: Clinical Cancer Research. Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies, 06-09 May 2017, Boston, MA. American Association for Cancer Research , p. 18.